Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

A high prognostic nutritional index (PNI) is associated with good prognosis in patients with esophageal cancer. However, nutritional status often decreases during neoadjuvant therapy. Functional tooth units (FTUs) provide an index for the status of posterior occlusal support. We have previously reported that low PNI is related to low FTUs. The purpose of this study was to retrospectively examine whether the status of occlusal support relates to changes in PNI during neoadjuvant therapy in patients with esophageal cancer. This study included 34 patients who underwent neoadjuvant therapy before esophagectomy (32 men, 2 women; age, 36-82 years) in 2012 at Okayama University Hospital. Patients were divided into the good occlusal support group (FTUs ≥ 11, = 18) or poor occlusal support group (FTUs < 11, = 16), and changes in PNI during neoadjuvant therapy were investigated. PNI decreased significantly after neoadjuvant therapy, particularly in the good occlusal support group, and became more dispersed after neoadjuvant therapy. Decreases in PNI after neoadjuvant therapy showed a significant positive correlation with good occlusal support by multiple regression analysis ( = 0.03). The proportions of patients provided with nutritional intervention ( = 0.02) or early dental intervention ( = 0.04) were lower in the good occlusal support group than in the poor occlusal support group. Even in patients with esophageal cancer with good occlusal support experienced significant declines in PNI during neoadjuvant therapy, potentially due to delayed nutritional and dental interventions. Early multidisciplinary interventions are thus recommended for all patients, regardless of preoperative dental or nutritional status.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11679835PMC
http://dx.doi.org/10.3390/nu16244383DOI Listing

Publication Analysis

Top Keywords

neoadjuvant therapy
40
occlusal support
40
good occlusal
20
support group
20
patients esophageal
16
esophageal cancer
16
pni neoadjuvant
16
neoadjuvant
10
therapy
10
occlusal
10

Similar Publications

A major cause of cancer death, colorectal cancer is becoming more common in younger people. The comparative effectiveness of robotic versus laparoscopic total mesorectal excision (TME) as surgical interventions for mid-low rectal cancer following neoadjuvant chemoradiotherapy (nCRT) remains uncertain. To systematically evaluate oncological, perioperative, and survival outcomes of robotic versus laparoscopic surgery for mid-low rectal cancer following nCRT.

View Article and Find Full Text PDF

The association of pre-neoadjuvant SUVmax and post-neoadjuvant change in SUVmax on FDG-PET with survival after oesophagectomy for cancer.

J Gastrointest Surg

September 2025

Department of Upper Gastrointestinal and Hepatobiliary Surgery, Royal Prince Alfred Hospital, Sydney, Australia; RPA Institute of Academic Surgery, Sydney, Australia; School of Medicine, University of Sydney, Sydney, Australia; Surgical Outcomes Research Centre (SOuRCe), Sydney, Australia.

Background: 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is currently widely used in staging and re-staging oesophageal cancer after neoadjuvant therapy. The maximal standardized uptake value (SUVmax) is a reproducible parameter that may predict survival. This study aimed to determine the prognostic significance of SUVmax and the change in SUVmax after neoadjuvant treatment (ΔSUVmax) on overall and disease-free survival.

View Article and Find Full Text PDF

ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma.

Cell Rep Med

August 2025

Department of Thoracic Surgery, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Shanghai Institute of Thoracic Oncology, Shanghai 200030, China. Electronic address:

The diagnostic accuracy of circulating tumor DNA (ctDNA) for detecting molecular residual disease (MRD) after multimodal treatment remains unclear. In a prospective cohort of 132 patients with locally advanced esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant chemoradiotherapy (nCRT) followed by clinical response evaluation and surgery, tumor-informed personalized-panel and fixed-panel ctDNA assays are applied to serial blood samples. Personalized ctDNA assay demonstrates a superior baseline detection rate (99.

View Article and Find Full Text PDF

Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal adenocarcinoma.

Surgery

September 2025

Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Vienna, Austria; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA; Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heide

Introduction: Very early recurrence in pancreatic ductal adenocarcinoma has been defined as recurrence ≤3 months after resection. Besides others, neoadjuvant treatment is delivered based on the assumption of preoperative eradication of micrometastasis as well as local downstaging. Prognostic factors of very early recurrence after neoadjuvant treatment remain largely unexplored.

View Article and Find Full Text PDF

Castleman disease (CD) is a rare lymphoproliferative disorder with unique clinicopathological features, including two distinct clinical subtypes categorized as unicentric (UCD) and multicentric (MCD). UCD usually involves a single lymph node site presenting with no or minimal local symptoms. Histologically, most UCD cases exhibit regressive hyaline vascular germinal centers, characterized by penetrating vessels, dendritic hyperplasia/dysplasia, and increased interfollicular vascularity.

View Article and Find Full Text PDF